MSB Q3 Financial Results and Operational Highlights
Filed with ASX · · 9 pages · English
In the deck
Story so far
Earlier from Mesoblast
- S&P DJI Announces March 2022 Quarterly Rebalance
- Second Quarter Results Presentation
- Ulcerative Colitis & Crohns Results Presented at ECCO
- Appendix 4C Quarterly Activity Report
- FDAs OTAT Agrees to Primary Endpoint for Back Pain
Later from Mesoblast
- Third Quarter Results Presentation
- Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
- Reinstatement to Quotation
- US$45 Million Private Placement to Major Shareholders
- Preliminary Final Report
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast